Anthem Biosciences, an India-based CDMO, submitted a filing (PDF) at the end of 2024 to announce its plans for a 33.95 ...

(Reuters) -Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion-rupee ($397 million) initial public ...

The Bengaluru-based pharma company is run by Ajay Bhardwaj, a former Biocon executive, who is the founder, CEO and Managing Director at Anthem Biosciences. The company was incorporated in 2006.

Anthem Biosciences files for a $397 million IPO amid India’s record-breaking year for public listings. The Bengaluru-based ...

The latest health updates include Anthem Biosciences' IPO, France's bird flu outbreaks impacting disease-free status, China's ...

Indian contract drugmaker Anthem Biosciences files for $397 million IPO amid booming Indian market for public offerings.

India-based drug manufacturer Anthem Biosciences has its sights on going public with an IPO that could raise 34 billion ...

Anthem Biosciences, a CRDMO specializing in drug discovery, development and manufacturing, has filed draft papers with Sebi ...

Anthem Biosciences has filed for a Rs 3,395-crore IPO consisting entirely of an offer for sale by promoters and shareholders. The funds will not benefit the company directly but go to selling parties.

Indian drugmaker Anthem Biosciences filed for a 33.95-billion-rupee ($397 million) initial public offering, draft papers ...

The proposed initial public offer (IPO) is entirely an offer for sale (OFS) worth ₹3,395 crore by promoters, investors and ...